| Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer (NCT01580696) | COL George Peoples, MD, FACS | 2012-04-01 |
| CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer (NCT01652079) | Massachusetts General Hospital | 2012-04-01 |
| Observation of Bevacizumab Plus Front-line Chemotherapy in Patients With Ovarian Cancer (NCT01982500) | Hellenic Oncology Research Group | 2012-03-01 |
| Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT01670799) | New Mexico Cancer Research Alliance | 2012-03-01 |
| Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers (NCT01523678) | Belgian Gynaecological Oncology Group | 2012-02-01 |
| Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer (NCT01535157) | South Plains Oncology Consortium | 2012-02-01 |
| Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand (NCT01511055) | Mayo Clinic | 2012-01-01 |
| DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer (NCT00603460) | University of Pennsylvania | 2012-01-01 |
| An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors (NCT01618136) | Eisai Limited | 2012-01-01 |
| TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer (NCT01493505) | Amgen | 2012-01-01 |
| Evaluation of Prognostic Factors for Tubo-ovarian Cancer in France (NCT05204342) | University Hospital, Montpellier | 2012-01-01 |
| Endocrine Disruptors and Life STILe in Breast Cancer Development (NCT05748353) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2012-01-01 |
| Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma. (NCT04284631) | Port Said University hospital | 2012-01-01 |
| Fallopian Tube Removal as a Method of Ovarian Cancer Prevention: A Descriptive Study (NCT01544049) | University of Washington | 2011-12-01 |
| Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer (NCT01416038) | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 2011-12-01 |
| Treg, Th17 Cells, NKT in Epithelial Ovarian Tumor (NCT03779399) | Medical University of Lublin | 2011-12-01 |
| Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer (NCT01471483) | Memorial Sloan Kettering Cancer Center | 2011-11-08 |
| A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer (NCT01469793) | Genentech, Inc. | 2011-11-01 |
| A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) (NCT01482715) | pharmaand GmbH | 2011-11-01 |
| Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer (NCT01485874) | Hoosier Cancer Research Network | 2011-11-01 |
| Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer (NCT01388621) | WiSP Wissenschaftlicher Service Pharma GmbH | 2011-10-01 |
| Studying Biomarkers in Samples From Younger Patients With Malignant Germ Cell Tumor Progression (NCT01433224) | Children's Oncology Group | 2011-10-01 |
| Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia (NCT01444456) | Amgen | 2011-10-01 |
| A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers (NCT01521325) | Morphotek | 2011-09-01 |
| Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting (NCT01432015) | Gynecologic Oncology Associates | 2011-09-01 |
| Hypodontia and Ovarian Cancer (NCT01470235) | University of Aarhus | 2011-09-01 |
| A Survivorship Care Plan for Gynaecological Cancer Patients (NCT01582906) | Royal Marsden NHS Foundation Trust | 2011-08-01 |
| A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) (NCT01357161) | Merck Sharp & Dohme LLC | 2011-07-26 |
| Validation of a Nutrition Screening Tool (NCT01851928) | Royal Marsden NHS Foundation Trust | 2011-07-01 |
| Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (NCT01376505) | Robert Wesolowski | 2011-06-21 |
| CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors (NCT01386502) | National Cancer Institute (NCI) | 2011-06-15 |
| Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids (NCT01256268) | H. Lee Moffitt Cancer Center and Research Institute | 2011-06-13 |
| Safety and Pharmacokinetics of Intraoperative Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) With Cisplatin to Treat Platinum-sensitive Recurrent Ovarian Cancer (NCT01387399) | University Hospital, Bonn | 2011-06-01 |
| INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer (NCT01379989) | Mario Negri Institute for Pharmacological Research | 2011-06-01 |
| Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer (NCT01358071) | AGC Biologics S.p.A. | 2011-06-01 |
| Patient Reported Symptoms in Ovarian Cancer (PRECISION) (NCT01422265) | Genentech, Inc. | 2011-06-01 |
| ICON8: Weekly Chemotherapy in Ovarian Cancer (NCT01654146) | Medical Research Council | 2011-06-01 |
| A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA) Defective Tumours (NCT01432145) | University of Oxford | 2011-05-01 |
| Pelvic Floor Disorders in Survivors of Gynecologic Malignancies (NCT01370122) | Abramson Cancer Center at Penn Medicine | 2011-05-01 |
| Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer (NCT01220154) | David O'Malley | 2011-04-28 |
| Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED) (NCT01170650) | Endocyte | 2011-04-22 |
| AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) (NCT01281254) | Amgen | 2011-04-18 |
| HYPAZ: Hypertension Induced by Pazopanib (NCT01392352) | Cambridge University Hospitals NHS Foundation Trust | 2011-04-01 |
| Study of Circulating Tumoral DNA in Ovarian Cancer (NCT01350908) | Institut Curie | 2011-04-01 |
| ROGYcare: The Impact of a Cancer Survivorship Care Plan on Patient Reported Outcomes and Health Care Providers (NCT01185626) | Lonneke van de Poll-Franse | 2011-04-01 |
| Epidemiology of Ovarian Cancer in Taiwan (NCT01465750) | National Taiwan University Hospital | 2011-04-01 |
| A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT01312389) | Abramson Cancer Center at Penn Medicine | 2011-04-01 |
| Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer (NCT01137071) | Recepta Biopharma | 2011-04-01 |
| A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck (NCT01059643) | Eli Lilly and Company | 2011-04-01 |
| A Trial of FANG™ Vaccine for Participants With Ovarian Cancer (NCT01309230) | Gradalis, Inc. | 2011-03-08 |
| Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer (NCT01196741) | University College, London | 2011-03-01 |
| Distinction Between Lung Cancer and Gynecological Cancers by Canine Scent Detection (NCT01383408) | Schillerhoehe Hospital | 2011-03-01 |
| Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers (NCT01237067) | National Cancer Institute (NCI) | 2011-02-07 |
| Panitumumab and Gemcitabine in Relapsed Ovarian Cancer (NCT01296035) | Women and Infants Hospital of Rhode Island | 2011-02-01 |
| Phase II ABT-888 With Cyclophosphamide (NCT01306032) | National Cancer Institute (NCI) | 2011-01-12 |
| Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer (NCT01196559) | The Catholic University of Korea | 2011-01-01 |
| Whole Body Diffusion MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Ovarian Cancer and Peritoneal Metastasis (NCT01242436) | Universitaire Ziekenhuizen KU Leuven | 2011-01-01 |
| Circulating Lymphatic Progenitor Cell and Lymph Node Metastasis (NCT01268956) | Hospital Universitari de Bellvitge | 2011-01-01 |
| Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer (NCT01131039) | Emory University | 2011-01-01 |
| Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive (NCT01262040) | Memorial Sloan Kettering Cancer Center | 2010-12-14 |
| Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer (NCT01065441) | Michael Har-Noy | 2010-12-01 |
| A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer (NCT01239732) | Hoffmann-La Roche | 2010-12-01 |
| Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer (NCT01017809) | NYU Langone Health | 2010-12-01 |
| Perioperative Morbidity in Gyneco-oncology According to the Procedure : Coelioscopy Versus Robot-assisted Coelioscopy (NCT01247779) | Centre Oscar Lambret | 2010-12-01 |
| Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules (NCT01226316) | AstraZeneca | 2010-12-01 |
| Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer (NCT01644825) | National Cancer Institute, Naples | 2010-12-01 |
| MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011) (NCT01227941) | Tesaro, Inc. | 2010-11-01 |
| Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer (NCT01253681) | Amgen | 2010-11-01 |
| Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies (NCT01242072) | Alaunos Therapeutics | 2010-11-01 |
| TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer (NCT01204749) | Amgen | 2010-11-01 |
| Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer (NCT01248962) | Memorial Sloan Kettering Cancer Center | 2010-11-01 |
| Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission (NCT01248273) | Memorial Sloan Kettering Cancer Center | 2010-11-01 |
| Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab (NCT01223235) | Memorial Sloan Kettering Cancer Center | 2010-10-01 |
| Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy (NCT01223248) | Memorial Sloan Kettering Cancer Center | 2010-10-01 |
| Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian (NCT01219777) | Ritu Salani | 2010-09-01 |
| Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer (NCT01202890) | New Mexico Cancer Research Alliance | 2010-09-01 |
| Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer (NCT01031381) | University of Pittsburgh | 2010-09-01 |
| Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers (NCT01149434) | University of Utah | 2010-09-01 |
| A Controlled Study of Quality of Life and it's Related Factors Among Gynecological Cancer Survivors (NCT01187706) | National Taiwan University Hospital | 2010-08-01 |
| Consolidation Whole Abdominal Intensity-Modulated Radiation Therapy (IMRT) in Advanced Ovarian Cancer (NCT01180504) | University Hospital Heidelberg | 2010-08-01 |
| Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer (NCT01216813) | Royal Marsden NHS Foundation Trust | 2010-08-01 |
| Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer (NCT01188876) | Massachusetts General Hospital | 2010-08-01 |
| Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer (NCT01187602) | University of Virginia | 2010-08-01 |
| WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer (NCT01144442) | Masonic Cancer Center, University of Minnesota | 2010-07-27 |
| Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer (NCT01166737) | AGO Study Group | 2010-07-01 |
| Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer (NCT01105650) | Masonic Cancer Center, University of Minnesota | 2010-07-01 |
| Use of Palliative Performance and Symptom Distress Scales in Older Patients With Advanced Ovarian Cancer (NCT01175967) | UNC Lineberger Comprehensive Cancer Center | 2010-06-01 |
| Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission (NCT01246440) | Grupo Español de Investigación en Cáncer de Ovario | 2010-06-01 |
| Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity (NCT01163552) | St. Luke's-Roosevelt Hospital Center | 2010-06-01 |
| Autologous OC-DC Vaccine in Ovarian Cancer (NCT01132014) | Abramson Cancer Center at Penn Medicine | 2010-05-01 |
| Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin (NCT01012336) | Samsung Medical Center | 2010-05-01 |
| Retrospective Study of Ovarian Cancer Patients With Brain Metastasis (NCT01258881) | National Taiwan University Hospital | 2010-04-01 |
| Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer (NCT01104675) | CASI pharmaceuticals, Inc. | 2010-04-01 |
| The Effect of Guided Imagery and Music Therapy on Post-Operative Recovery After Gynecological Oncology Surgery (NCT01284075) | University of Minnesota | 2010-04-01 |
| Ex Vivo Evaluation of the Interest of the Association of Platinum With a Molecule BH3-mimetic ABT-737 in Samples of Ovarian Tumors (NCT01440504) | Centre Francois Baclesse | 2010-04-01 |
| Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer (NCT00993655) | Canadian Cancer Trials Group | 2010-03-03 |
| Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor (NCT01459653) | Sandoz | 2010-03-01 |
| Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome (NCT00946283) | Rutgers, The State University of New Jersey | 2010-03-01 |
| A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (NCT01570582) | Korean Gynecologic Oncology Group | 2010-03-01 |
| A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer (NCT01113957) | AbbVie (prior sponsor, Abbott) | 2010-03-01 |